Novartis Agrees To $642m US Settlement Over Kickbacks
Faizan Hashmi Published July 02, 2020 | 05:40 PM
Swiss pharmaceutical giant Novartis has agreed to pay more than $642 million to settle a lawsuit that accused it of paying kickbacks to doctors, among other allegations, the US Department of Justice said
Washington, (UrduPoint / Pakistan Point News - 2nd Jul, 2020 ) :Swiss pharmaceutical giant Novartis has agreed to pay more than $642 million to settle a lawsuit that accused it of paying kickbacks to doctors, among other allegations, the US Department of Justice said.
Part of the settlement was related to the company's use of three foundations to funnel payments to cover costs for patients taking its multiple sclerosis drug Gilenya and kidney cancer drug Afinitor.
Another part centered on alleged bribing of doctors to prescribe the company's medication.
"Through this settlement and others, the government has demonstrated its commitment to ensuring that drug companies do not use kickbacks to influence the drugs prescribed by doctors or purchased by patients," Assistant Attorney General Jody Hunt said Wednesday.
Novartis is accused of having hosted tens of thousands of speaker programs and events which the Department of Justice said were used to bribe physicians.
In one example, the company chose doctors who already prescribed high volumes of Novartis drugs to serve as paid speakers, as a means of inducing them to continue writing or write more prescriptions.
Representatives often dropped doctors from the speaker program if they failed to increase prescriptions, the Department of Justice said.
"For more than a decade, Novartis spent hundreds of millions of Dollars on so-called speaker programs, including speaking fees, exorbitant meals and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis' drugs," said acting US Attorney Audrey Strauss for the Southern District of New York.
The Department of Justice said the activity was the result of decisions made by top management at Novartis' North American headquarters in New Jersey.
Under the settlement, Novartis will participate in a five-year corporate integrity agreement with the Department of Health and Human Services to address company conduct.
The company's CEO Vas Narasimhan described the settlement as "an important milestone on our journey to build trust with society".
Recent Stories
HEC reviews curricula for environmental sciences degree programme
ICC Asia looking forward to an action-packed Asia Cricket Week
Yuvraj Singh named ICC Men’s T20 World Cup 2024 Ambassador
Greece hands Olympic flame to 2024 Paris Games hosts
Two Kyiv hospitals evacuating over feared Russian strikes
World must act on neurotech revolution, say experts
Charles & Catherine's cancer diagnoses
Champions Alcaraz and Sabalenka through in Madrid Open
King Charles to resume some public duties during cancer treatment: palace
US defense chief announces $6 bn in security aid for Ukraine
Heavy rains cause damage to Spezand-Taftan railway track
Woman stabbed in Israel, attacker killed: police
More Stories From Business
-
Finance minister reviews progress on FBR digitalization
6 hours ago -
US stocks rebound on tech earnings, London hits new record
6 hours ago -
US approves gene therapy treatment for hemophilia
5 hours ago -
KATI president for inclusion of agri sector in tax net
5 hours ago -
Ahsan chairs 13th CPEC-JCC preparatory meeting, reviews arrangements for high-level delegation’s v ..
7 hours ago -
Police to take every step for security of business community: IGP
7 hours ago
-
WB director, Planning minister discuss reforms in development projects
7 hours ago -
IP rights crucial in achieving SDG : Jam Kamal
9 hours ago -
FBR’s data protection efforts commended by OECD assessment team
8 hours ago -
US stocks rebound on tech earnings, London hits new record
9 hours ago -
SECP-IFSB workshop highlights Pakistan's progress in Islamic Finance Development
9 hours ago -
SBP to announce monetary policy on April 29
9 hours ago